Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment

A novel mechanism behind the resistance of breast cancer brain metastases to HER2- or PI3K-targeted therapies has been discovered, and a treatment strategy has now been identified that may overcome this resistance.